NZ723402B2 - Compositions of selenoorganic compounds and methods of use thereof - Google Patents

Compositions of selenoorganic compounds and methods of use thereof Download PDF

Info

Publication number
NZ723402B2
NZ723402B2 NZ723402A NZ72340216A NZ723402B2 NZ 723402 B2 NZ723402 B2 NZ 723402B2 NZ 723402 A NZ723402 A NZ 723402A NZ 72340216 A NZ72340216 A NZ 72340216A NZ 723402 B2 NZ723402 B2 NZ 723402B2
Authority
NZ
New Zealand
Prior art keywords
composition
subject
different compounds
medicament
methylseleno
Prior art date
Application number
NZ723402A
Other versions
NZ723402A (en
Inventor
Zi Jian Lan
Ronan Power
Original Assignee
Alltech Inc
Filing date
Publication date
Priority claimed from PCT/US2014/029542 external-priority patent/WO2015137983A1/en
Application filed by Alltech Inc filed Critical Alltech Inc
Publication of NZ723402A publication Critical patent/NZ723402A/en
Publication of NZ723402B2 publication Critical patent/NZ723402B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Abstract

The present application relates to compositions comprising selenium compounds, such as 5’-Methylselenoadenosine, Se-Adenosyl-L-homocysteine, Gamma-glutamyl-methylseleno-cysteine, a compound of Formula (I), Formula (II), or Formula (III), and combinations thereof, and methods of using the same for modulating glucose metabolism in a subject.

Claims (7)

CLAIMS :
1. Use of a composition for the manufacture of a medicament for replacing insulin in a subject, the composition comprising at least three different compounds selected from the group consisting of 5'-Methylselenoadenosine, Se-Adenosyl-L-homocysteine, and Gamma- glutamyl-methylseleno-cysteine, wherein the medicament is formulated for administration of the composition to the subject; wherein the composition contains at least about 0.033% (w/v) of each of the at least three different compounds.
2. Use of a composition for the manufacture of medicament for enhancing insulin activity in a subject, the composition comprising at least three different compounds selected from the group consisting of 5'-Methylse­ lenoadenosine, Se-Adenosyl-L-homocysteine, and Gamma-glutamyl-methylseleno-cysteine, wherein the medicament is formulated for administration of the composition to the subject; wherein the composition contains at least about 0.033% (w/v) of each of the at least three different compounds.
3. Use of a composition for the manufacture of a medicament for inhibiting glucose production in a subject, composition comprising at least three different compounds selected from the group consisting of 5'-Methylselenoadenosine, Se-Adenosyl-L-homocysteine, and Gamma- glutamyl-methylseleno-cysteine, wherein the medicament is formulated for administration of the composition to the subject; wherein the composition contains at least about 0.033% (w/v) of each of the at least three different compounds.
4. Use of a composition for the manufacture of a medicament for modulating glucose metabolism in a subject, the composition comprising at least three different compounds selected from the group consisting of 5'-Methylse­ lenoadenosine, Se-Adenosyl-L- homocysteine, and Gamma-glutamyl-methylseleno-cysteine, wherein the medicament is formulated for administration of the composition to the subject; wherein the composition contains at least about 0.033% (w/v) of each of the at least three different compounds.
5. The use of any one of claims 1, 2, 3 or 4, wherein the composition comprises at least 0.1% (w/v) of 5'-Methylselenoadenosine.
6. The use of any one of claims 1, 2, 3 or 4, wherein the composition further comprises insulin.
7. A composition comprising from 0.033% (w/v) to 99.9% (w/v) of at least three different compounds selected from the group consisting of 5'-Methylselenoadenosine, Se-Adenosyl- L-homocysteine, and Gamma-glutamyl-methylseleno­cysteine; and further comprising a carrier.
NZ723402A 2016-08-30 Compositions of selenoorganic compounds and methods of use thereof NZ723402B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2014/029542 WO2015137983A1 (en) 2014-03-14 2014-03-14 Compositions of selenoorganic compounds and methods of use thereof
US14/855,128 US9642874B2 (en) 2014-03-14 2015-09-15 Compositions of selenoorganic compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
NZ723402A NZ723402A (en) 2024-11-29
NZ723402B2 true NZ723402B2 (en) 2025-03-04

Family

ID=

Similar Documents

Publication Publication Date Title
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
AU2016213805A1 (en) Nuclear transport modulators and uses thereof
WO2008067119A3 (en) Novel compounds
MY168201A (en) Agricultural And Horticultural Fungicidal Composition
PH12014500083B1 (en) Fungicidal substituted 2-[2-halogenalkyl-4-(phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds
HK1215579A1 (en) Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
BR112015008717A2 (en) compound, pharmaceutical composition, method of treating type II diabetes, use of the compound of formula (i), medication for treating type II diabetes
BR112014003063A2 (en) "Antibacterial cyclopenta [c] pyrrol substituted 3,4-dihydro-1h- [1,8] naphthyridinones, pharmaceutical composition comprising said compounds, processes for their preparation and use".
CA2920410C (en) Thienopiperidine derivative and use thereof
BR112014002958A2 (en) "Antibacterial piperidinyl substituted 3,4-dihydro-1h- [1,8] naphthyridinones, pharmaceutical composition comprising said compounds, processes for their preparation and use".
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
WO2016025933A3 (en) Substituted polycyclic antibacterial compounds
PH12018500377A1 (en) Novel annelated benzamides
PH12018500378A1 (en) Novel annelated phenoxyacetamides
PH12015502684A1 (en) New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof
IL276194B2 (en) Compounds or pharmaceutical compositions comprising them for use in the treatment of paininhibiting
TW200626593A (en) Novel compounds
WO2015042414A8 (en) Multicyclic compounds and methods of using same
MX2015007116A (en) New substituted 1,4-dithiine derivatives and their use as fungicides.
NZ587490A (en) Anti-Microbial Compounds containing compounds with a sugar substituent
WO2013106756A3 (en) Antimicrobial agents
PH12021552032A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
HK1215197A1 (en) Gel compositions
SG11201903014PA (en) Urea derivative